Elektrochemotherapie – Möglichkeiten lokaler Tumorkontrolle

 

 Permissions and Reprints

Zusammenfassung

Die Elektrochemotherapie (ECT) ist ein Verfahren, bei dem mittels kurzer elektrischer Pulse lokal eine Erhöhung der Zellmembranpermeabilität erzielt wird. Gleichzeitig applizierte Chemotherapeutika können so in Tumorzellen gelangen und dort ihre Wirkung entfalten. Die Methode ist einfach anzuwenden und Nebenwirkungen sind gering. Sie eignet sich zur Therapie kutaner und subkutaner Tumoren, die durch chirurgische oder andere Verfahren nicht oder nur schwer zu behandeln sind. Bei fortgeschrittenen Tumorerkrankungen kann so eine gute lokale Tumorkontrolle erreicht und die Lebensqualität der Betroffenen, die häufig unter Blutungen und Geruchsentwicklung der Metastasen leiden, verbessert werden. Bei alten und/oder multimorbiden Patienten ist die Therapie einfach durchzuführen und weitgehend schonend. Neuere Erkenntnisse über immunologische Effekte bei der Kombination aus ECT und Immuntherapien eröffnen möglicherweise neue Therapieoptionen für Patienten mit metastasiertem Melanom.

Abstract

Electrochemotherapy (ECT) allows the delivery of chemotherapeutic agents into tumors through electroporation. The method is easy to apply and side effects are mild. When surgical resection or other procedures are contraindicated or impossible to perform, ECT offers an alternate treatment option for cutaneous and subcutaneous metastases. By this means in patients with advanced disease local tumor control can be achieved. Also quality of life, which is often impaired due to bleeding and fetor, can be improved. Even elderly and patients with many concomitant illnesses can profit from ECT. Furthermore, insights on immunologic effects when ECT and immunotherapies are combined, offer new treatment options for patients with malignant melanoma in the future.

• Literatur

• 1 Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 1993; 2: 228-236
  PubMedGoogle Scholar
• 2 Guida M, Campana LG, Curatolo P et al. Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective study. J Surg Oncol 2016; 114: 246-253
  CrossrefPubMedGoogle Scholar
• 3 Di Monta G, Caracò C, Benedetto L et al. Electrochemotherapy as ‘new standard of care’ treatment for cutaneous Kaposi’s sarcoma. Eur J Surg Oncol 2014; 40: 61-66
  CrossrefPubMedGoogle Scholar
• 4 Neumann E, Schaefer-Ridder M, Wang Y et al. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982; 1: 841-845
  PubMedGoogle Scholar
• 5 Landström F, Ivarsson M, Von Sydow AK et al. Electrochemotherapy – Evidence for Cell-type Selectivity In Vitro. Anticancer Res 2015; 35: 5813-5820
  PubMedGoogle Scholar
• 6 Miklavčič D, Mali B, Kos B et al. Electrochemotherapy: from the drawing board into medical practice. Biomed Eng Online 2014; 13: 29
  CrossrefPubMedGoogle Scholar
• 7 Mir LM, Gehl J, Sersa G et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator^TM by means of invasive or non-invasive electrodes. Eur J Cancer Suppl. 2006; 4: 14-25
  PubMedGoogle Scholar
• 8 Maglietti F, Tellado M, Olaiz N et al. Combined local and systemic bleomycin administration in electrochemotherapy to reduce the number of treatment sessions. Radiol Oncol 2016; 50: 58-63
  PubMedGoogle Scholar
• 9 Matthiessen LW, Johannesen HH, Hendel HW et al. Electrochemotherapy for large cutaneous recurrence of breast cancer: a phase II clinical trial. Acta Oncol 2012; 51: 713-721
  Google Scholar
• 10 Kreuter A, van Eijk T, Lehmann P et al. Elektrochemotherapie bei fortgeschrittenen Hauttumoren und Hautmetastasen – eine retrospektive multizentrische Auswertung. JDDG 2015; 13: 308-316
  PubMedGoogle Scholar
• 11 Deroose JP, Grünhagen DJ, Eggermont AM M et al. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases. Melanoma Res 2015; 25: 427-431
  CrossrefPubMedGoogle Scholar
• 12 Kroon BB R, Noorda EM, Vrouenraets BC et al. Isolated limb perfusion for melanoma. Surg Oncol Clin N Am 2008; 17: 785-794, viii – ix
  CrossrefPubMedGoogle Scholar
• 13 Mali B, Jarm T, Snoj M et al. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013; 39: 4-16
  CrossrefPubMedGoogle Scholar
• 14 Campana LG, Mali B, Sersa G et al. Electrochemotherapy in non-melanoma head and neck cancers: a retrospective analysis of the treated cases. Br J Oral Maxillofac Surg 2014; 52: 957-964
  CrossrefPubMedGoogle Scholar
• 15 Dossett LA, Ben-Shabat I, Olofsson Bagge R et al. Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. Ann Surg Oncol 2016; 23: 2330-2335
  CrossrefPubMedGoogle Scholar
• 16 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen, D. K. e. V. (DKG) und Fachgesellschaften e. V. (AWMF) und Deutschen Krebshilfe(DKH). S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms. 2016
  PubMedGoogle Scholar
• 17 National Institute for Health and Care Excellence (NICE). Electrochemotherapapy for primary basal cell carcinoma and primary squamous cell carcinoma Interventional procedure guidance. 2014
  PubMedGoogle Scholar
• 18 Stratigos A, Garbe C, Lebbe C et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 1989-2007
  CrossrefPubMedGoogle Scholar
• 19 Lebbe C, Becker JC, Grob J-J et al. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 2396-2403
  CrossrefPubMedGoogle Scholar
• 20 Edhemovic I, Gadzijev EM, Brecelj E et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treat 2011; 10: 475-485
  CrossrefPubMedGoogle Scholar
• 21 Sersa G, Mikiavcic D, Cemazar M et al. Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompetent and immunodeficient mice. Bioelectrochemistry Bioenerg 1997; 43: 279-283
  PubMedGoogle Scholar
• 22 Calvet CY, Mir LM. The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev 2016; 35: 165-177
  CrossrefPubMedGoogle Scholar
• 23 Sersa G, Teissie J, Cemazar M et al. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 2015; 64: 1315-1327
  CrossrefPubMedGoogle Scholar
• 24 Daud AI, DeConti RC, Andrews S et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-5903
  CrossrefPubMedGoogle Scholar
• 25 Mozzillo N, Simeone E, Benedetto L et al. Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Oncoimmunology 2015; 4: e1008842
  CrossrefPubMedGoogle Scholar
• 26 Valpione S, Campana LG, Pigozzo J et al. Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. Radiol Oncol 2015; 49: 71-74
  PubMedGoogle Scholar